Introduction
Apo B, the major protein component of LDL, contains the binding site for the LDL receptor and consequently plays a pivotal role in the metabolism of the lipoprotein, by facilitating its cellular uptake and degradation (1, 2) . In recent years, attention has focused on the receptor as the mediator of cholesterol homeostasis in the body, and we now know that a variety of mutations in this protein may produce gross disturbances in plasma LDL levels (3, 4) . Now, with the isolation of the gene coding for apo B (5), we are able to use the techniques of molecular biology to analyze the contribution that the ligand might make to alterations in lipoprotein metabolism.
DNA probes for the human apo B gene have recently been isolated (6-9) and a number of common restriction fragment length polymorphisms (RFLP)' have been described (9-1 1).
One of these, an RFLP detected using the restriction enzyme Xba I, has been shown in normal individuals to be associated with variations in plasma cholesterol and triglyceride (12) (13) (14) . The same polymorphism has also been reported to represent an independent risk factor for ischemic heart disease (15) , although there is not universal agreement on this point (16) . In this study, we use three polymorphisms ofthe apo B gene locus to examine the relationship between variation in the apo B gene and the metabolism of LDL in a group of individuals with moderate hyperlipemia.
Methods
Subjects. Volunteers aged between 40 and 60 yr were identified as hyperlipidemic during an opportunistic screening program in the city of Glasgow. Those detected were given dietary advice designed to correct their lipid abnormality and reassessed after 2 mo. At this point, potential sufferers from familial hypercholesterolemia were diagnosed on the basis ofrecognized criteria (17) and excluded ifthey had tendon xanthomata or a first-degree relative (particularly a child) with raised LDL cholesterol. Two subjects with total cholesterol values of 8.5 and 8.3 mmol/liter were rejected on this basis. None of the remaining 19 unrelated Caucasian subjects (4 male, 15 female; Table I ) who failed to respond adequately to the diet, had a strong family history of premature cardiovascular disease (i.e., more than one affected first-degree relative aged < 55 yr). Two presented with xanthelasmata, two with corneal arcus, and two with angina of effort (Table I) . Their plasma cholesterol levels were, on average, 7.69±0.73 mmol/liter and their diet was maintained during the evaluation of LDL metabolic parameters. 60 mg potassium iodide was given thrice daily for 3 d before and 2 wk after the study to prevent thyroidal sequestration of radioiodide. Biochemical tests showed that none of the subjects suffered from hepatic, renal, or endocrine disease and none had overt ischemic heart disease. All subjects gave informed consent to the study, which was approved by the Ethical Committee of Glasgow Royal Infirmary.
Metabolic studies. LDL turnover was assessed in the patients using a protocol described elsewhere (18, 19) . Briefly, autologous LDL (d = 1.03-1.05 kg/liter) was prepared by rate zonal ultracentrifugation (20) and divided into two aliquots, which were labeled separately with 1251I and 1311 (21) . The latter was then subjected to modification with 1, 2-cyclohexanedione, which blocks the arginyl residues on its protein moiety (22) and provides a tracer ofreceptor-independent LDL metabolism (18, 19) . Such modification prevents interaction of the lipoprotein with the receptor and denies it access to the receptor-dependent degradation pathway. Plasma clearance of each tracer was followed over a 2-wk period and the radioactive decay curves were constructed and analyzed using the SAAM 29 computer program (23) . This gave fractional clearance rates (FCRs) for the native and chemically modified LDL that were used to obtain values for total, receptor-independent, and, by difference, receptor-mediated catabolism of the lipoprotein (18, 19) . Plasma apo LDL concentrations were determined from calculations based on serial LDL cholesterol measurements and on compositional data derived from analyses of the isolated lipoprotein (24) . The absolute clearance rate for LDL apoprotein was then calculated as the product of the total FCR and the plasma LDL pool (i.e., apo LDL concentration times the plasma volume). This parameter is commonly expressed per kilogram of body weight, and under the steady state conditions of the study equals the synthetic rate of the protein. Separate absolute clearance rates can also be calculated for the receptor-dependent and independent routes as the product of the apo LDL pool and the FCR can be determined for each pathway.
DNA analysis. Blood was collected into 2.0 mg/ml K2 EDTA and stored at -20'C until analysis. DNA was prepared from these specimens by the Triton Xl00 lysis method (25) , and a 5.0-,gg aliquot was digested using a panel of enzymes (Eco RI, Xba I, Pvu II, Xmn I, and Nco I) at 2-10 U of enzyme per microgram of DNA according to the supplier's instructions (Anglian Biotech, Colchester, England).
The fragments generated in each digest were separated by agarose electrophoresis and transferred to Hybond filters (Amersham Corp., Amersham, England) by Southern blotting.
Polymorphisms of the apo 1 gene were detected ( Fig. 1 ): (a) by hybridizing the two Xba I digest fragments designated XI (8.6 kb) and X2 (3.5 kb), with the 3.5-kb probe pABC3.5 (I1); (b) in an Eco RI digest by hybridizing the two fragments, RI (10.5 kb) and R2 (12.5 kb), with the cDNA probe pAB3 ( 11) ; and (c) after digestion with Msp'I and probing with PH2 (a 2-kb Hind III fragment subcloned from an apo B genomic recombinant). Multiple hybridizing fragments could be demonstrated (1 1). Those 2.6 kb and larger were designated Ml and those 2.2 kb and smaller were designated M2. Polymorphisms of the LDL receptor gene were detected using a 1.9-kb Bam HI cDNA (26, 27) after digestion with either Pvu' II or Nco I.
Apolipoprotein AI/CIII/AIV gene cluster polymorphisms were identified' using (a) a 2.2-kb Pst I fragment (28) ofthe apo AI gene after Xmn I digestion and (b) a 1.0-kb Pvu II fragment (29) ofthe C-III gene after Pvu II digestion.
All probes were labeled with 32P dCTP at a specific activity of 800 Ci/mmol (Amersham Corp.) by a random oligonucleotide priming method (30). The hybridization, filter washing, and autoradiographic procedures are described elsewhere (28) .
Statistical analysis. Statistical analysis was carried out by the Minitab program (State College, PA). A one-way analysis of variance was performed to test the null hypothesis that kinetic variation was not associated with genetic variation detected by the different RFLPs. The F statistic' was employed to test the significance of differences between the genotypes. We considered significance to be at the 0.05 level.
Results
The 19 subjects could be divided into three groups on the basis of the polymorphisms detected using the Xba I endonuclease (Table I ). There was no difference in body weight or mean age, nor in the plasma'concentrations of cholesterol, triglyceride, LDL cholesterol, or apoprotein between those with the genotype XJXl (absence of cutting site) and those with the genotype X2X2. There were also no significant differences in these parameters when the subjects were grouped according to the polymorphisms detected with the Msp I and the Eco RI enzymes. Similarly, the gross composition of LDL was not altered in individuals of different Xba I genotype (Table II) .
However, the metabolic properties of LDL did differ between the genotype groups. The catabolic rate of LDL apoprotein measured as the fraction of the plasma pool catabolized each day (FCR), was significantly higher in individuals with the XJXJ genotype compared with those with X2X2 (F = 9.18; P < 0.025). The subjects with the genotype XJX2 had an intermediate mean FCR. Simultaneous with the injection of native lipoprotein, subjects received a tracer of cyclohexanedione-treated LDL that permitted the estimation of receptor-dependent versus receptor-independent removal (Table  III) . This revealed that the difference in overall catabolism was due to an increase in the fraction and amount of LDL degraded by the receptor route. Subjects of XIXJ genotype exhibited a 58% higher receptor-mediated FCR than those with the genotype X2X2 (F = 9.08; P < 0.025) and cleared 65% more LDL protein through this pathway. No such difference was observed in the fraction of LDL degraded by receptor-independent mechanisms. Likewise, when the synthetic rate of LDL apoprotein was calculated, no significant'association with genotype was observed, although this parameter was highly variable within the groups.
There was a weak association between LDL apoprotein clearance rate and the apo B polymorphism detected using Msp I (Table IV) It is difficult to make a definitive diagnosis of familial hypercholesterolemia in individuals with moderately elevated cholesterol levels using available techniques. Clinical criteria remain the best guide, but even here, lack of available family history may cloud the issue. In this study, commonly accepted exclusion criteria were set for individuals with familial hypercholesterolemia (see Methods). However, it is important to note in interpreting the data that these criteria are not absolute.
Although individuals with familial hypercholesterolemia were'excluded from the study and all of the subjects had similar plasma lipid and lipoprotein levels, the FCR for LDL var- Table III. ied by up to 50%. This variability was related to the apo B genotype of the individual. The group of five subjects with genotype XJXJ had a 22% higher total FCR than the six who had genotype X2X2. More detailed examination of the cause of this difference, using a receptor-blocked LDL tracer, revealed that the difference was due to an increased flux through the receptor pathway. Both the proportion of the plasma LDL apoprotein pool and the amount cleared via receptors was significantly elevated in XJXJ individuals. It is unlikely that these observations can be explained by changes of the constitutive activity of the receptor. Rather, they indicate that variations in the structure of the ligand LDL are responsible. Our data suggest that apo B produced in X2X2 individuals has a perturbed structure that diminishes its ability to interact with the receptor on cell membranes. Since it is known that only one B protein is present on each particle, this hypothesis also implies that individuals who are heterozygous for the polymorphism would produce two forms of LDL (one receptor active, the other relatively inactive) and would express an intermediate FCR (Table III) . The DNA sequence change that creates the Xba I restriction site occurs at the third base of the codon for threonine 2,488 in apo B (36) . No amino acid change results, and so it is unlikely that the Xba I polymorphism itself is functionally significant. Rather, this site is probably in linkage disequilibrium with an important change elsewhere in the coding region. One possibility is that the important mutation lies in the putative receptor binding site (5), i.e., between amino acids 3,147-3,157 or 3,351-3,367, a region close to the Xba I cutting site.
The findings presented here also suggest a mechanism for the association of Xba I genotype and plasma cholesterol in the normal population (12) (13) (14) . In subjects with normal lipid levels, there is a strong relationship between the receptor-mediated FCR and LDL concentration (31) . The observed higher plasma cholesterol in individuals of X2X2 versus XJX1 genotype thus might be explained by the production of a relatively receptor-inactive apo B in the former group that would lead to accumulation of LDL in the circulation. Where the influence of synthesis becomes predominant, as in our present cohort of hypercholesterolemic patients, this relationship with plasma LDL concentration would be diminished. It is not yet clear whether the metabolic changes described in this study relate to the higher incidence of ischemic heart disease reported in one study to be associated with the Xl allele (15) . However, if the trend toward higher LDL apoprotein synthesis in the XJXJ group (Table IV) is confirmed in subsequent studies, then it may point to the importance of LDL flux and plasma concentration as risk markers for ischemic heart disease.
